Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047301 | 0.93 | MEN1 (0.51) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL1043782 | 0.91 | MEN1 (0.54) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL74431 | 0.88 | CYP1A2 (0.50) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL10338308 | 0.85 | MEN1 (0.60) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL9114592 | 0.83 | CYP1A2 (0.63) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL4270834 | 0.79 | TSHR (0.64) | DRD2DRD4DRD3CYP1A2CYP2D6 | |
| SCHEMBL8778513 | 0.79 | LTA4H (0.57) | LMNACYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL167606 | 0.79 | DRD2 (0.56) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL316199 | 0.78 | MAOB (0.47) | DRD2DRD4DRD3CYP1A2CYP2D6 | |
| SCHEMBL2526196 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0159584-B1 | N-(AZOLYLCARBAMOYL)-HYDROXYL AMINES AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1989-01-18 | — | — | EP | claimed |
| US-4678798-A | PLANTS, SEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | claimed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| CN-102895230-A | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMA CO LTD | 2013-01-30 | — | — | CN | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| CN-101801933-A | quinolone derivative | ASTELLAS PHARMA INC | 2010-08-11 | — | — | CN | disclosed |
| EP-0421227-A2 | 1-Hydroxy-1,2,4-triazole derivatives and fungicides containing them and growth regulators | BASF Aktiengesellschaft (DE) | 1991-04-10 | — | — | EP | disclosed |
| US-4678798-A | PLANTS, SEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | disclosed |
| US-4122282-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4099014-A | BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4085139-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4081478-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4073808-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-4033989-A | 9-Deoxy-PGF2 Analogs | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4016184-A | PROSTAGLANDINS, BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DRD2 2614/4885DRD4 888/4885DRD3 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.